LUMEN ET VIRTUS · Feb 23, 2026

Impact of semaglutide use on lean mass and the risk of sarcopenia: an integrative review of clinical evidence

By Viana VG, Nunes JDC, Giacomelli JR et al.

Semaglutide has emerged as an effective pharmacological strategy for treating obesity and type 2 diabetes mellitus, promoting significant weight loss. However, its effects on lean mass, muscle function, and the risk of sarcopenia remain a subject of debate, especially in vulnerable populations, such as older adults. The objective of this study was to critically analyze the available clinical evidence regarding the impact of semaglutide use on lean mass and the risk of sarcopenia. This is a narrative literature review conducted through systematic searches of the PubMed/MEDLINE, SciELO, and ScienceDirect databases, covering articles published between 2015 and 2025. Randomized clinical trials, observational studies, and retrospective cohorts conducted in humans that evaluated the effects of semaglutide on body composition, lean mass, and functional outcomes related to sarcopenia were included. In total, 19 studies were analyzed. Semaglutide was consistently associated with significant weight loss, predominantly attributed to a reduction in fat mass. An absolute reduction in lean mass was observed, generally proportionally smaller relative to total weight loss, resulting in a favorable redistribution of body composition. Effects on muscle function were heterogeneous, with functional preservation in nonelderly adults and a greater risk of functional decline in older and clinically vulnerable populations. It is concluded that semaglutide promotes favorable changes in body composition; however, its effects on lean mass and muscle function depend on the patient's clinical profile. Although there is no direct causal evidence of sarcopenia induction, monitoring of body composition and muscle function is recommended, especially in older adults, as is the adoption of integrated strategies, such as resistance training and adequate protein intake, to mitigate potential musculoskeletal risks.

doi.org/10.56238/levv17n57-073Open accessInterventions

AgingResearch.News